A single injection of anti-PD-L1 blocking antibody induces a transient reduction in tau pathology in P301S (PS19) mouse model of tauopathy
Kertser, A.; Baruch, K.; Schwartz, M.
Show abstract
Blocking the inhibitory PD-1/PD-L1 immune checkpoint pathway has been shown to arrest cognitive decline and reduce multiple aspects of brain pathology in various mouse models of amyloidosis and tauopathy. In this study, we evaluated whether anti-PD-L1 treatment would be effective in a tauopathy model characterized by rapidly progressing pathology. Using the P301S (PS19) transgenic mouse model, we found that a single injection of anti-PD-L1 antibody significantly attenuated cognitive deficits, with effects detectable 1-month post-treatment, aligned with the kinetics reported in other models. This cognitive benefit was observed irrespective of microglial TREM2 signalling. The effect on brain pathology was transient; phosphorylated tau in the brain, and total tau in the cerebrospinal fluid were significantly reduced 14 days post-treatment but not at 28 days. These findings indicate that PD-L1 blockade is effective across multiple disease models, while emphasizing the importance of carefully monitoring the timing of effect assessments, treatment outcomes, and dosing frequency, especially in models with accelerated disease progression.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Hippocampal subfield vulnerability to α-synuclein pathology precedes neurodegeneration and cognitive dysfunction 95%
- Sex-dimorphic neuroprotective effect of CD163 in an α-synuclein mouse model of Parkinson's disease 94%
- A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies 94%
Similar papers in this journal
- Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia 95%
- Cognitive and GABAergic protection by hAPPSw,Ind and hTauVLW coexpression: a model of Non-Demented with Alzheimer's disease Neuropathology 95%
- Plasma amyloid beta ratios in autosomal dominant Alzheimers disease: the influence of genotype 95%
Similar papers in this journal
Similar papers in this journal
- Long-term Nrf2-driven microglial repopulation mitigates microgliosis, neuronal loss and cognitive deficits in tauopathy 95%
- Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer's disease 95%
- Neuroinflammation, Depressive Affect, and Amyloid Burden in Alzheimer's Disease: Insights from the Kynurenine Pathway 93%